American Vanguard Corporation — Q2 2011 Form 10-Q
Business context and period. The filing reports unaudited results for the quarter and six months ended June 30, 2011. The company operates in one reportable segment, selling crop-protection and non-crop products. Unless otherwise noted, amounts below are in millions of dollars.
Financial results and liquidity
| Metric | Q2 2011 | Q2 2010 | Six months 2011 | Six months 2010 |
|---|---|---|---|---|
| Net sales | $80.4 | $52.2 | $147.8 | $98.9 |
| Gross profit | $32.0 | $19.2 | $60.3 | $38.2 |
| Gross margin | 39.8% | 36.9% | 40.8% | 38.6% |
| Operating income | $10.7 | $3.6 | $19.9 | $7.4 |
| Net income | $6.0 | $1.6 | $11.0 | $3.5 |
| Diluted EPS | $0.22 | $0.06 | $0.40 | $0.13 |
- Second-quarter sales rose 54%; first-half sales increased 49%. Crop sales drove growth, while first-half non-crop sales declined 3%.
- Operating cash flow was $2.3 million for the first half, versus $8.4 million in the prior-year period. Receivables increased $41.0 million and inventory increased $6.6 million, absorbing cash amid higher seasonal sales. Capital expenditures were $2.3 million.
- At June 30, cash was $10.0 million; current assets were $169.0 million and current liabilities $81.0 million, or approximately 2.1x current-asset coverage. Total debt was $71.0 million, up from $62.1 million at year-end 2010. Stockholders’ equity was $177.7 million.
- The company reported compliance with its credit covenants and up to $75 million of additional borrowing capacity under its credit facility. The $137 million secured facility matures January 10, 2016; substantially all assets are pledged. A swap covers $45 million, or 75%, of term-loan debt.
Material changes and management commentary
- Growth reflected strong corn and cotton markets, wet Midwest weather, customer restocking, and product-line acquisitions completed in 2010. Management estimated organic year-over-year sales growth of approximately 21% in Q2.
- Acquired products and higher sales of soil insecticides, including Thimet, Counter, Mocap and Nemacur, contributed to crop growth. Folex sales also increased with earlier supply availability and the acquired Def product line. PCNB restrictions reduced sales.
- Management attributed improved gross margins to manufacturing efficiencies, product mix, higher-margin acquired products, and pricing actions on generic products. Operating expenses rose $5.6 million in Q2, including higher selling, research and administrative costs; the quarter included a $0.22 million one-time retiree medical charge.
- First-half results included a $0.55 million non-cash debt-extinguishment charge. Further acquisition accounting added $6.8 million to intangible assets and related liabilities for estimated earn-out payments.
- Management expected Q3 Folex sales to be lower year over year following strong Q2 sales. The filing provides no broader numerical earnings or revenue guidance; it cautions that first-half results are not necessarily indicative of full-year results.
Risks, contingencies and other notable matters
- PCNB: The USEPA’s stop-sale order remained in effect, and the agency’s review had no predictable timetable or outcome. At June 30, the company held $18.5 million of related inventory and $5.1 million of related intangible assets, with no reserve for a potential domestic loss; cancellation could require an asset write-down. For Canadian PCNB, approximately $1.3 million of channel inventory was unpaid; the company considered a $0.5–$1.0 million loss probable and recorded a $0.5 million contingency.
- DBCP litigation: Approximately 100 claims were reported overall, including newly filed Louisiana federal cases involving more than 200 plaintiffs and older Louisiana state cases involving about 314 plaintiffs. The company said losses were not probable or reasonably estimable and recorded no contingency. It intends to defend the cases.
- Other disclosed risk factors include product demand and weather, regulation, competition and pricing, foreign-exchange movements, and supply or capacity constraints. Management reported effective disclosure controls and no material change in internal controls during the quarter.
Key facts for investors to verify
- Whether the PCNB regulatory review, litigation, or Canadian inventory developments change the potential impairment or recorded contingency.
- Whether receivables, inventory, and program accruals convert to cash as seasonal sales normalize; first-half operating cash flow was substantially below net income.
- Debt levels, covenant headroom, collateral requirements, and the interest-rate and swap exposure under the secured credit facility.
- How much sales growth and margin performance are repeatable versus attributable to acquisitions, weather, crop-market conditions, and timing of Folex sales.